BHV3000-202: Phase 2: A Double-Blind, Placebo Controlled, Crossover Trial of BHV-3000 (Rimegepant) for Treatment Refractory Trigeminal Neuralgia
Phase: PHASE2
Conditions: Trigeminal Neuralgia
Sponsor: Pfizer

CCI

CCI
CCI
CCI

CCI

CCI

CCI

CCI

CCI

CCI

CCI

CCI
CCI

PPD
PPD